Epidemiological characteristics and prognosis of medulloblastoma

doi:10.3877/cma.j.issn.2095-123X.2020.04.009

Abstract

Abstract:

Medulloblastoma (MDB) is the most common primary malignant brain tumor in children, which is second only to pediatric astrocytoma and accounts for about 40% of posterior fossa tumors in children. We found that tumor metastasis (cerebrospinal fluid implantation), subtotal tumor resection and large cell/anaplastic MDB were statistically significant adverse prognostic factors. WNT subtype, standard risk group, M0 stage, postoperative radiotherapy combined with chemotherapy, older age (≥3 years old) at diagnosis and total tumor resection were favorable factors for prognosis. This review focuses on the epidemiological characteristics of pediatric MDB and the primary prognostic factors of MDB.

Key words: Medulloblastoma, Children, Epidemiology, Prognosis

Lihua Chen, Kai Sun, Wenjin Chen, Yong Xia, Hongtian Zhang, Ruxiang Xu. Epidemiological characteristics and prognosis of medulloblastoma[J]. Chinese Journal of Brain Diseases and Rehabilitation(Electronic Edition), 2020, 10(04): 239-243.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhnkjbykfzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-123X.2020.04.009

https://zhnkjbykfzz.cma-cmc.com.cn/EN/Y2020/V10/I04/239

References 30

[1]	Millard NE, De Braganca KC. Medulloblastoma[J]. J Child Neurol, 2016, 31(12): 1341-1353.
[2]	Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system[J]. Acta Neuropathol, 2007, 114(2): 97-109.
[3]	Das U, Appaji L, Kumari BS, et al. Spectrum of pediatric brain tumors: a report of 341 cases from a tertiary cancer center in India[J]. Indian J Pediatr, 2014, 81(10): 1089-1091.
[4]	Chan AW, Tarbell NJ, Black PM, et al. Adult medulloblastoma: prognostic factors and patterns of relapse[J]. Neurosurgery, 2000, 47(3): 623-631; discussion 631-622.
[5]	Khalil J, Chaabi S, Oberlin O, et al. Medulloblastoma in childhood: what effects on neurocognitive functions?[J]. Cancer Radiother, 2019, 23(5): 370-377.
[6]	Bokun J, Grujicic D, Skender-Gazibara M, et al. Management and treatment of children with medulloblastoma in serbia, a middle-income country[J]. J BUON, 2018, 23(4): 1156-1162.
[7]	孔垂广，白威，叶玉勤,等.小儿神经外科疾病的单中心研究[J].中华神经外科杂志, 2019, 35(12): 1231-1235.
[8]	Alexiou GA, Moschovi M, Stefanaki K, et al. Epidemiology of pediatric brain tumors in Greece (1991-2008). Experience from the Agia Sofia children’s hospital[J]. Cent Eur Neurosurg, 2011, 72(1): 1-4.
[9]	Bartlett F, Kortmann R, Saran F. Medulloblastoma[J]. Clin Oncol (R Coll Radiol), 2013, 25(1): 36-45.
[10]	Hovestadt V, Ayrault O, Swartling FJ, et al. Medulloblastomics revisited: biological and clinical insights from thousands of patients[J]. Nat Rev Cancer, 2020, 20(1): 42-56.
[11]	Massimino M, Biassoni V, Gandola L, et al. Childhood medulloblastoma[J]. Crit Rev Oncol Hematol, 2016, 105: 35-51.
[12]	Packer RJ, Gajjar A, Vezina G, et al. Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma[J]. J Clin Oncol, 2006, 24(25): 4202-4208.
[13]	Mathew RK, O’Kane R, Parslow R, et al. Comparison of survival between the UK and US after surgery for most common pediatric CNS tumors[J]. Neuro Oncol, 2014, 16(8): 1137-1145.
[14]	Wang C, Yuan XJ, Jiang MW, et al. Clinical characteristics and abandonment and outcome of treatment in 67 Chinese children with medulloblastoma[J]. J Neurosurg Pediatr, 2016, 17(1): 49-56.
[15]	Padovani L, Sunyach MP, Perol D, et al. Common strategy for adult and pediatric medulloblastoma: a multicenter series of 253 adults[J]. Int J Radiat Oncol Biol Phys, 2007, 68(2): 433-440.
[16]	Yu J, Zhao R, Shi W, et al. Risk factors for the prognosis of pediatric medulloblastoma: a retrospective analysis of 40 cases[J]. Clinics(Sao Paulo), 2017, 72(5): 294-304.
[17]	Jiang T, Zhang Y, Wang J, et al. Impact of tumor location and fourth ventricle infiltration in medulloblastoma[J]. Acta Neurochir(Wien), 2016, 158(6): 1187-1195.
[18]	von Bueren AO, von Hoff K, Pietsch T, et al. Treatment of young children with localized medulloblastoma by chemotherapy alone: results of the prospective, multicenter trial HIT 2000 confirming the prognostic impact of histology[J]. Neuro Oncol, 2011, 13(6): 669-679.
[19]	Chang CH, Housepian EM, Herbert C Jr. An operative staging system and a megavoltage radiotherapeutic technic for cerebellar medulloblastomas[J]. Radiology, 1969, 93(6): 1351-1359.
[20]	Bowers DC, Gargan L, Weprin BE, et al. Impact of site of tumor recurrence upon survival for children with recurrent or progressive medulloblastoma[J]. J Neurosurg, 2007, 107(1 Suppl): 5-10.
[21]	Dufour C, Beaugrand A, Pizer B, et al. Metastatic medulloblastoma in childhood: Chang’s classification revisited[J]. Int J Surg Oncol, 2012, 2012: 245385.
[22]	Zeltzer PM, Boyett JM, Finlay JL, et al. Metastasis stage, adjuvant treatment, and residual tumor are prognostic factors for medulloblastoma in children: conclusions from the children’s cancer group 921 randomized phase III study[J]. J Clin Oncol, 1999, 17(3): 832-845.
[23]	Pogorzala M, Styczynski J, Wysocki M. Survival and prognostic factors in children with brain tumors: long-term follow-up single center study in Poland[J]. Anticancer Res, 2014, 34(1): 323-326.
[24]	Thompson EM, Hielscher T, Bouffet E, et al. Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup: a retrospective integrated clinical and molecular analysis[J]. Lancet Oncol, 2016, 17(4): 484-495.
[25]	Atallah A, Rady MR, Kamal HM, et al. Telovelar approach to pediatric fourth ventricle tumors: feasibility and outcome[J]. Turk Neurosurg, 2019, 29(4): 497-505.
[26]	Rutkowski S, von Hoff K, Emser A, et al. Survival and prognostic factors of early childhood medulloblastoma: an international meta-analysis[J]. J Clin Oncol, 2010, 28(33): 4961-4968.
[27]	Gatta G, Botta L, Rossi S, et al. Childhood cancer survival in Europe 1999-2007: results of EUROCARE-5-a population-based study[J]. Lancet Oncol, 2014, 15(1): 35-47.
[28]	Ramaswamy V, Remke M, Bouffet E, et al. Recurrence patterns across medulloblastoma subgroups: an integrated clinical and molecular analysis[J]. Lancet Oncol, 2013, 14(12): 1200-1207.
[29]	Ramaswamy V, Remke M, Bouffet E, et al. Risk stratification of childhood medulloblastoma in the molecular era: The current consensus[J]. Acta Neuropathol, 2016, 131(6): 821-831.
[30]	Khatua S, Zaky W. The biologic era of childhood medulloblastoma and clues to novel therapies[J]. Future Oncol, 2014, 10(4): 637-645.

Please choose a citation manager

Content to export